Trials of semaglutide in patients with Alzheimer’s and CagriSema in obese patients diabetes could give investors reason to be ...
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
As of 11:05 a.m. ET, Novo Nordisk stock is down a disheartening 20.8%, while both Lilly and Viking stocks are up 4.4% apiece.
Analysts have set 12-month price targets for Novo Nordisk, revealing an average target of $145.25, a high estimate of $160.00 ...
Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...
EUROPE’S Stoxx 600 closed slightly higher at the start of a holiday-shortened week, as a spike in Novo Nordisk shares boosted ...
European markets edge higher as Novo Nordisk rebounds, with gains led by healthcare and tech sectors despite lingering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback